PubMed · 3047331
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W M Hryniuk. 1988. More is better.. https://doi.org/10.1200/jco.1988.6.9.1365
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Polychemotherapy (CMF or CMF-like regimens) is the treatment of choice in premenopausal breast cancer patients with 1-3 positive nodes. In clinical practice, patients with abnormal biochemical tests of liver function are usually excluded from this potentially curative methotrexate-containing regimen in order to avoid worsening of hepatic damage. On the other hand, recent reports have shown a beneficial effect of methotrexate in a particular autoimmune liver disease such as primary biliary cirrhosis. We discuss the case of a female patient with breast cancer and primary biliary cirrhosis whose biochemical tests of liver function and the titer of antimitochondrial antibody persistently improved after treatment with 3 cycles of CMF. In conclusion, we suggest that the CMF regimen is potentially useful in patients with breast cancer and primary biliary cirrhosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.